Pfizer Inc on Monday struck a $43 billion deal to acquire Seagen Inc and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and generic competition for some top-selling drugs. Seagen marks Pfizer's largest purchase in a string of recent acquisitions utilizing a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment